Navigation Links
Sunesis Pharmaceuticals Receives Milestone Payment From Biogen Idec
Date:7/13/2009

SOUTH SAN FRANCISCO, Calif., July 13 /PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS), a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers, today announced that it has received a $1.5 million milestone payment from Biogen Idec (Nasdaq: BIIB) for the selection of a Raf kinase inhibitor development candidate for the treatment of cancer. Biogen Idec is currently conducting IND-enabling GLP preclinical work with the Raf kinase development candidate.

"While our internal efforts are focused on the successful development of voreloxin, we are extremely pleased by the continued progress being made by Biogen Idec to advance a Raf kinase inhibitor toward the clinic," said Daniel Swisher, Sunesis' Chief Executive Officer.

In August 2004 the companies entered into a collaboration to discover and develop small molecule cancer therapeutics targeting kinases, a family of cell signaling enzymes that play a major role in the progression of cancer. The research term of this collaboration ended in June of 2008. Sunesis retains an option to participate in the co-development and co-promotion of the Raf kinase inhibitor resulting from this collaboration.

About Sunesis Pharmaceuticals

Sunesis is a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. Sunesis has built a highly experienced cancer drug development organization committed to advancing voreloxin in multiple indications to improve the lives of people with cancer. For additional information on Sunesis Pharmaceuticals, please visit http://www.sunesis.com.

SUNESIS and the logo are trademarks of Sunesis Pharmaceuticals, Inc.

    Investor Contact:                           Media Contact:
    Sunesis Pharmaceuticals, Inc.               Sunesis Pharmaceuticals, Inc.
    Eric Bjerkholt                              Dan Weinseimer
    650-266-3717                                650-266-3739


'/>"/>
SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Sunesis Announces New Data on Voreloxin for Acute Myeloid Leukemia and Ovarian Cancer Will Be Presented at ASCO
2. Sunesis Reports Financial Results for the First Quarter 2009
3. Sunesis Pharmaceuticals Announces Up To $43.5 Million Financing
4. Sunesis Pharmaceuticals to Present at the Collins Stewart Fourth Annual Growth Conference
5. Sunesis Pharmaceuticals to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference
6. Sunesis Pharmaceuticals Presents Nonclinical Data on SNS-595 at the Annual Meeting of the American Association for Cancer Research
7. Sunesis Pharmaceuticals to Present at Healthcare Investor Conferences in March
8. Sunesis Pharmaceuticals SNS-595 Shows Clinical Activity in Patients With Relapsed or Refractory Acute Leukemias; Data Presented in Oral Session at 49th Annual Meeting of the American Society of Hematology
9. Sunesis Pharmaceuticals Reports New Option Grants Under NASDAQ Marketplace Rule 4350
10. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
11. Portola Pharmaceuticals Announces Several Scientific Presentations at International Society on Thrombosis and Haemostasis XII Congress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2017)... ... 2017 , ... Medic CE , a Career Step company, is sponsoring ... hosted by the Journal of Emergency Medical Services (JEMS). The free webinar, to be ... by Captain Rommie Duckworth, LP, a career fire captain as well as founder and ...
(Date:5/24/2017)... , ... May 24, 2017 , ... ... prominent for-profit and nonprofit hospitals and health systems in the nation and help ... their institutions, led professional organizations and been instrumental in developing successful hospital and ...
(Date:5/23/2017)... ... , ... Axiad IDS , a leading provider of trusted identities for ... company a “Top 25 Cybersecurity Companies 2017.” Axiad IDS received this honor ... proactively address potential cybersecurity threats before they happen. The annual list of ...
(Date:5/23/2017)... ... May 23, 2017 , ... ... and a 2017 Best in KLAS category winner, has named Daniel P. Bullington ... extend and enhance its technology platform and product offerings,” says Justin Neece, president. ...
(Date:5/23/2017)... ... May 23, 2017 , ... Drs. Allen Huang and Jeffrey ... in Las Vegas, NV, and the importance of treating it immediately. They are ... care for peri-implantitis, with or without a referral. As experienced periodontists and implant ...
Breaking Medicine News(10 mins):
(Date:5/3/2017)... 2017  Kalorama Information notes that transplant diagnostics ... year and this is projected to continue to ... (HSCT) or bone marrow transplants require histocompatibility between ... for this task. This according to a new ... The various PCR-based methodologies, Sanger sequencing and NGS ...
(Date:5/3/2017)... 2017  West Pharmaceutical Services, Inc. (NYSE: WST), ... drug administration, announced today that Fran DeGrazio ... and Diane Paskiet , Director, Scientific Affairs, ... on West,s expertise in the areas of safety ... providing commentary on updated industry guidance. ...
(Date:5/2/2017)... SYDNEY , May 2, 2017  George Clinical, ... Asia-Pacific region, and Vector Oncology, a ... research and data analytics, formally announced today that George ... immediately, the transaction has the dual purpose of ... scientifically led oncology trial delivery solutions throughout the ...
Breaking Medicine Technology: